Meningococcemia Clinical Trial
Official title:
Clinical and Laboratorial Factors Associated With the Severity of Meningococcal Disease
Verified date | February 2003 |
Source | University of Sao Paulo General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Brazil: Ethics Committee |
Study type | Observational |
Objectives:
Meningococcal disease (MD) is a complex catastrophic phenomenon that can converge rapidly to
irreversible septic shock, myocardial dysfunction, and profound coagulopathy. During
meningococcal sepsis and meningitis, a myriad of cells release cytokines within the
intravascular environment and subarachnoid space. Cytokines are key molecular messengers
that play key roles in orchestrating and mediating the metabolic, endocrine and coagulation
responses to meningococcal infection. The aim of the present study is to determine the
profile of different cytokines in serum and cerebrospinal fluid during MD, as well as relate
the level of these cytokines to severity of MD.
Design:
Prospective, nonrandomized study.
Setting:
Tertiary referral intensive care unit.
Patients:
Children and adults admitted with a clinical diagnosis of MD. Interventions: Blood and
cerebrospinal fluid will sample from children and adults with MD.
Status | Completed |
Enrollment | 100 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 6 Months to 75 Years |
Eligibility |
Inclusion Criteria: - clinical diagnostic of meningococcal disease Exclusion Criteria: - no meningococcal disease |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Brazil | University of São Paulo General Hospital - LIM-12 and LIM-56 | São Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital | Instituto de Infectologia Emílio Ribas |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | shock | low blood pressure | 24 hours | Yes |
Secondary | acute kidney injury | elevation of serum creatinine levels | 3 days | Yes |
Secondary | disseminated intravascular coagulation | plaquetopenia, coagulopathy | 24 hours | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00539032 -
Immunology and Safety of Menactra® in Children in Saudi Arabia
|
Phase 3 | |
Completed |
NCT00772070 -
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
|
Phase 2 | |
Completed |
NCT00700713 -
Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26
|
Phase 2 | |
Terminated |
NCT00772629 -
Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
|
Phase 2 | |
Completed |
NCT00777790 -
Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
|
Phase 2 | |
Completed |
NCT00771849 -
Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children
|
Phase 2 | |
Completed |
NCT00777257 -
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
|
Phase 4 |